Nautilus Biotechnolgy
NAUT
81 hedge funds and large institutions have $211M invested in Nautilus Biotechnolgy in 2026 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 16 increasing their positions, 15 reducing their positions, and 9 closing their positions.
178% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 9
85% more capital invested
Capital invested by funds: $114M → $211M (+$97.2M)
19% more funds holding
Funds holding: 68 → 81 (+13)
7% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 15
3.22% less ownership
Funds ownership: 46.16% → 42.94% (-3.2%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CA
Clearstead Advisors
Cleveland,
Ohio
|
+$5.72M |
| 2 |
Millennium Management
New York
|
+$623K |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$498K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$318K |
| 5 |
CAM
Crown Advisors Management
Larkspur,
California
|
+$246K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$494K |
| 2 |
Jane Street
New York
|
-$356K |
| 3 |
OAC
OMERS Administration Corp
Toronto,
Ontario, Canada
|
-$197K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$170K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$107K |
NAUT Hedge Fund Activity: Q1 2026 in Review
81 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in Nautilus Biotechnolgy (NAUT) for Q1 2026, worth a combined $211M — up 85% from $114M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new NAUT positions and 9 closed out — a net gain of 16 holders — while 16 added to existing stakes and 15 trimmed.
The largest buyer was Clearstead Advisors, opening a new position worth an estimated $5.72M. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $494K sold.
- 81 institutional investors held Nautilus Biotechnolgy (NAUT) as of Q1 2026, up from 68 in Q4 2025.
- Funds reported $211M of Nautilus Biotechnolgy stock for Q1 2026, up 85% quarter-over-quarter.
- 25 funds opened new Nautilus Biotechnolgy positions in Q1 2026 and 9 closed out, a net change of +16 holders.
- The largest Nautilus Biotechnolgy buyer in Q1 2026 was Clearstead Advisors, an estimated $5.72M added.
- The largest Nautilus Biotechnolgy seller in Q1 2026 was Alyeska Investment Group, an estimated $494K sold.
Based on aggregated 13F filings for Q1 2026.